|drug3428||To assess for development of IgG antibodies against SARS-CoV2 Wiki||0.71|
|drug3495||Two COVID-19 vaccine candidate (TMV-083) administrations - Low dose Wiki||0.71|
|drug2312||One COVID-19 vaccine candidate (TMV-083) administration - High dose Wiki||0.71|
|D058070||Asymptomatic Diseases NIH||0.35|
|D003333||Coronaviridae Infections NIH||0.32|
|D012327||RNA Virus Infections NIH||0.25|
There are 2 clinical trials
This will be a phase 1a randomized, open label, multi-center study with approximately 24 subjects. All subjects will receive standard of care (SOC) per institutional guidelines for treatment of hospitalized patients with COVID-19 infection. In addition to SOC, the brequinar group will receive 5 daily doses of brequinar 100 mg.
Description: Adverse events are new onset medical conditions.Measure: Safety/tolerability measured by rates of post randomization adverse events and hematology/chemistry safety labs. Time: Beginning at signing consent through Day 15.
Description: In-patient hospitalization, hospitalized in ICU-level care, or dischargedMeasure: Hospitalization status Time: Through Day 15
Description: Duration in days from admission to dischargeMeasure: Duration of hospitalization Time: Through Day 15
Description: National Early Warning Score (NEWS) 2. Composite score of respiration rate, oxygen saturation, systolic blood pressure, pulse, consciousness, and temperature.Measure: NEWS2 Score Time: Through Day 15
Description: Subject mortality statusMeasure: Mortality Time: Day 29
Description: Nasopharyngeal viral load by RT-PCR at days 1, 3, 5, 7, and 15Measure: SARS-CoV-2 nasopharyngeal viral load Time: Through Day 15
Description: Pro-inflammatory cytokines including TNFalpha, INFgamma, IL13, IL12p70, IL10, IL8, IL6, IL4 IL2, IL1-beta and erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), D-dimer, serum ferritin, and fibrinogenMeasure: Inflammatory markers Time: Through Day 15
Description: Plasma concentration of dihydroorotateMeasure: DHO Concentration Time: Through Day 15
Description: Plasma concentration of brequinarMeasure: Brequinar Concentration Time: Through Day 15
This study will assess the efficacy and safety of DHODHi (brequinar) as an antiviral via 5 days of treatment of participants with positive COVID-19 and at least one symptom of COVI019 in an out-patient setting. The study is multi-center, randomized, and placebo-controlled.
Description: Quantitative SARS-CoV-2 viral loadMeasure: SARS-CoV-2 viral load Time: Day 29
Description: Safety measured by rates of AEs and SAEs including laboratory assessmentsMeasure: Rates of AEs and SAEs including laboratory assessments Time: Day 29
Description: Duration of viral sheddingMeasure: Viral shedding duration Time: Day 29
Description: Percentage of subjects requiring admission as an inpatient for >24 hoursMeasure: Hospital Admission Time: Day 29
Data processed on January 01, 2021.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports